Dylan Stoy, PSI’s Therapeutic Strategy Director, is dedicated to conducting and executing better clinical studies in PSI’s core therapeutic areas. Dylan has a wealth of experience in the oncology indication, with research interests in targeted drug delivery systems and optimizing the design and conduct of studies. Dylan has overseen clinical research from various roles including onsite research, design and trial conduct, clinical operations oversight, project management, and therapeutic strategy.
Dylan and his team are devoted to making participation for sites and patients in complex oncology studies more attainable and ensuring that both PSI’s teams and your study sites are highly trained and properly supported to handle any challenges your program might encounter. Dylan works closely with the core business units within PSI, overseeing research throughout the study lifecycle, providing strategic leadership to our teams and collaborators (both internally and externally), and delivering corporate-wide trainings to make PSI your full-service CRO for all things oncology.